Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

Authors: K. J. Yoon¹; Philip M. Potter¹; Mary K. Danks¹

Source: Current Medicinal Chemistry - Anti-Cancer Agents, Volume 5, Number 2, March 2005 , pp. 107-113(7)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.

Keywords: enzyme prodrug therapy; hsv-tk gcv; Herves Simplex Virus-Thymidine Kinase Ganciclovir; cd 5-fc; cytosine deaminase 5-fluorocytosine; pnpase 2-f-araa; purine nucleoside phosphorylase 2-fluoroarabinosyl

Document Type: Review article

DOI: 10.2174/1568011053174837

Affiliations: 1: Department of Molecular Pharmacology, St. Jude Children's Research Hospital.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax